Statistics for ETS REVISIÓN RÁPIDA N° 42-2021. Adalimumab, golimumab, infliximab, tocilizumab, etanercept y rituximab: tratamiento de pacientes con artritis reumatoide refractaria al tratamiento convencional
Total visits
| views | |
|---|---|
| ETS REVISIÓN RÁPIDA N° 42-2021. Adalimumab, golimumab, infliximab, tocilizumab, etanercept y rituximab: tratamiento de pacientes con artritis reumatoide refractaria al tratamiento convencional | 83 |
Total visits per month
| views | |
|---|---|
| May 2025 | 12 |
| June 2025 | 1 |
| July 2025 | 2 |
| August 2025 | 4 |
| September 2025 | 0 |
| October 2025 | 0 |
| November 2025 | 0 |
File Visits
| views | |
|---|---|
| REVISION_RAPIDA_042_2021 | 73 |